Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Chipotle Mexican Grill, Inc. (CMG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Chipotle Mexican Grill, Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Chipotle Mexican Grill, Inc. trades at $35.26 (market cap $45.22B). The key difference: Alnylam Pharmaceuticals, Inc. and Chipotle Mexican Grill, Inc. are close in size by market cap, and Chipotle Mexican Grill, Inc. is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | CMG | |
|---|---|---|
Market Cap | $39.89B | $45.22B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $56.00 |
52-Week Low | $278.09 | $28.17 |
Enterprise Value | $38.15B | $49.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Chipotle Mexican Grill (CMG) trades at $35.25, up 1.88% on the day, with strong analyst support and consistent earnings beats. The stock shows bullish technical signals with support at $34 and resistance at $35. Revenue grew to $11.93 billion in 2025, with a net income margin of 11.96%, though margins have narrowed slightly from prior years. Recent news highlights operational focus and menu innovation as growth drivers.
Outlook remains positive with a $40.46 consensus price target, but risks include cost pressures and competitive threats. The stock offers growth potential through expansion and operational excellence, yet investors should monitor margin trends and consumer spending shifts in the volatile restaurant sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Chipotle Mexican Grill, Inc.
Chipotle Mexican Grill is the largest fast-casual chain restaurant in the United States, with systemwide sales of $7.5 billion in 2021. The Mexican concept is entirely company-owned, with a footprint of more than 3,000 stores, heavily indexed to the United States (though the firm maintains a small presence in Canada, the U.K., France, and Germany). Chipotle sells burritos, burrito bowls, tacos, quesadillas, and beverages, with a selling proposition built around competitive prices, high-quality food sourcing, speed of service, and convenience. The company generates its revenue entirely from restaurant sales and delivery fees.
Read more on CMG →
